Is secukinumab 300 mg appropriate for an adult with generalized pustular psoriasis who has developed Cushingoid changes from prolonged oral corticosteroid therapy and cannot use retinoids?

Secukinumab 300mg for Generalized Pustular Psoriasis

Secukinumab 300mg is an appropriate and effective biologic option for generalized pustular psoriasis (GPP), particularly in this patient who cannot tolerate corticosteroids or retinoids. While the AAD-NPF guidelines provide only limited evidence for palmoplantar pustulosis (Strength B recommendation), emerging research demonstrates strong efficacy specifically for GPP, making it a suitable choice in this clinical scenario 1, 2, 3.

Evidence Supporting Secukinumab for GPP

Guideline Recommendations

• The 2019 AAD-NPF guidelines recommend secukinumab 300mg for palmoplantar pustulosis with a Strength B recommendation based on Level III evidence 1
• While GPP is not explicitly addressed in the main recommendations, the guidelines establish secukinumab 300mg as the preferred dose over 150mg for psoriasis variants (Strength A) 1
• The British Association of Dermatologists (2017) considers secukinumab as a first-line biologic agent for adults with psoriasis 1

Clinical Trial Evidence for GPP

The most compelling evidence comes from a 2016 Japanese Phase III open-label study specifically in GPP patients:

• 83.3% of patients achieved treatment success at week 16 (primary endpoint), with 9 of 12 patients rated as "very much improved" and 1 as "much improved" 3
• Pustular lesions improved as early as week 1 and resolved by week 16 in most patients 3
• Improvements were sustained throughout 52 weeks with good tolerability 3
• Two non-responders were successfully up-titrated from 150mg to 300mg 3

Real-World Evidence

A 2025 Japanese post-marketing surveillance of 99 GPP patients provides robust real-world data:

• Approximately 90% of patients achieved complete or partial response from week 2 through week 52 2
• 47.83% achieved complete remission (no symptoms) by week 52 2
• Mean PASI scores decreased from 17.26 at baseline to 1.18 at week 16 (90.18% reduction) 2
• Quality of life improved dramatically, with 57.14% achieving DLQI scores of 0/1 at week 52 2
• No new safety signals emerged during long-term treatment 2

Dosing Regimen

The recommended dosing for GPP based on FDA labeling and clinical evidence:

• Loading phase: 300mg subcutaneously at weeks 0,1,2,3, and 4 4, 3
• Maintenance phase: 300mg every 4 weeks thereafter 4, 3
• Each 300mg dose is given as one subcutaneous injection of 300mg or two injections of 150mg 4

Advantages in This Clinical Context

For this patient with Cushingoid changes from prolonged corticosteroid use and retinoid intolerance:

• Steroid-sparing effect: Secukinumab allows for corticosteroid discontinuation, addressing the Cushingoid complications 2, 3
• No retinoid requirement: Functions as monotherapy without need for retinoids 3
• Rapid onset: Clinical improvement visible as early as week 1, with substantial improvement by week 2 2, 3
• Sustained efficacy: Long-term control maintained through 52 weeks and beyond 2, 3

Safety Profile

Secukinumab demonstrated acceptable safety in GPP populations:

• Adverse events occurred in 51.58% of patients, with serious adverse events in 12.63% 2
• Most common adverse events: nasopharyngitis, urticaria, diabetes mellitus, and arthralgia 3
• No unexpected safety signals compared to use in plaque psoriasis 2, 3
• Neutralizing antibodies rare (<0.4%) and not associated with loss of efficacy 1

Alternative Considerations

While ixekizumab has a Strength B recommendation specifically for GPP in the AAD-NPF guidelines 1, secukinumab has more robust published evidence in GPP populations. Spesolimab (IL-36 receptor antibody) is FDA-approved for acute GPP flares but was not available when these guidelines were published 5.

Monitoring Recommendations

Based on guideline recommendations for biologic therapy:

• Assess initial response at time points appropriate for the drug (weeks 12-16) 1
• Monitor regularly during therapy (every 6 months) 1
• Evaluate for active or latent tuberculosis prior to initiation 4
• Complete age-appropriate vaccinations before starting treatment 4

If inadequate response occurs, consider dose escalation or switching to an alternative IL-17 inhibitor (ixekizumab) or IL-36 inhibitor (spesolimab) based on the specific clinical scenario 1, 5.